You are viewing: US Cancer Biomarkers Market analysis
Part of: Cancer Biomarkers Market (Global)

The US Cancer Biomarkers Market was valued at $7800 Million in 2026 and projected to reach to $15157.3 Million by 2031, representing a compound annual growth rate of 11.7%. The US cancer biomarkers market is poised for sustained growth through 2031, driven by increasing adoption of precision medicine in oncology and growing demand for early cancer detection solutions.

US Cancer Biomarkers Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Cancer Biomarkers Market Trends and Insights

  • This expansion reflects the US healthcare system's increasing adoption of precision oncology and molecular diagnostics to improve patient outcomes.
  • The US market benefits from advanced healthcare infrastructure, substantial R&D investment, and strong regulatory frameworks that accelerate biomarker discovery and clinical validation. Driving this growth, the US sees rising demand for early cancer detection, personalized treatment strategies, and companion diagnostics across major cancer types.
  • The US pharmaceutical and diagnostics industries are investing heavily in liquid biopsy technologies, genomic profiling, and AI-enabled biomarker identification.
  • Between 2026 and 2031, the US market will be shaped by increasing reimbursement coverage, growing clinical evidence supporting biomarker-guided therapies, and expanding applications in immunotherapy and targeted cancer treatments. The US competitive landscape features both established diagnostic companies and innovative biotech firms developing next-generation biomarker solutions.
  • Regulatory support from the FDA and integration of biomarkers into US clinical practice guidelines continue to accelerate market penetration and adoption across oncology centers nationwide..

Key Market Statistics

  • CAGR (2026-2031) 11.7% CAGR
  • Market Size, 2026 ~USD 7800 Million
  • Forecast, 2031 ~USD 15157.3 Million
  • Country US

US Cancer Biomarkers Market Overview

Market Valuation Growth :

The US cancer biomarkers market is valued at $7,800 million in 2026 and is projected to reach $15,157.3 million by 2031, representing a robust 11.7% CAGR driven by precision oncology adoption.

Advanced Healthcare Infrastructure :

The US benefits from world-class diagnostic laboratories, cutting-edge sequencing technologies, and integrated electronic health records that accelerate biomarker discovery and clinical implementation.

Strong R&D Investment :

Substantial funding from NIH, private biotech firms, and pharmaceutical companies fuels innovation in liquid biopsy, genomic profiling, and immunotherapy biomarkers across US research institutions.

Precision Oncology Adoption :

US healthcare providers increasingly utilize molecular diagnostics and companion diagnostics to enable personalized cancer treatment, improving patient outcomes and driving market expansion.

US Cancer Biomarkers Market Dynamics

  • Healthcare providers are investing heavily in molecular diagnostic capabilities, while FDA approvals of companion diagnostics and liquid biopsy tests continue to expand clinical applications.
  • Reimbursement improvements and integration of biomarker testing into standard treatment protocols further accelerate market penetration across major US healthcare systems. Key growth catalysts include rising cancer incidence, aging population demographics, and technological advances in next-generation sequencing and artificial intelligence-driven biomarker analysis.
  • Pharmaceutical companies' focus on targeted therapies and immunotherapies necessitates robust biomarker companion diagnostics.
  • Strategic partnerships between diagnostic companies and healthcare providers, combined with increasing patient awareness of personalized medicine, will sustain the market's 11.7% CAGR through 2031..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    In Vitro Diagnostics

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Enzyme-Linked Immunosorbent Assay (ELISA)
    • Dna Microarrays
    • Assay Kits
    • Microarrays
    Top Companies
    • ROCHE HOLDINGS AG
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Abbott Laboratories
    • Biomerieux s.a.

      Key Takeaways

      • The US cancer biomarkers market will nearly double from $7.8B in 2026 to $15.2B by 2031, driven by precision oncology adoption.
      • The US 11.7% CAGR outpaces global growth, reflecting strong healthcare spending and advanced diagnostic infrastructure.
      • The US market is propelled by liquid biopsy innovation, companion diagnostics, and FDA regulatory support for biomarker-guided therapies.
      • The US reimbursement landscape and clinical guideline integration are key accelerators for biomarker adoption through 2031.

      Cancer Biomarkers Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment LUNG CANCER (Cancer Type)
      Forecast Period 2026–2031
      Growth Rate CAGR of 11.6% from 2026 to 2031
      Largest Segment OMICS TECHNOLOGIES (Profiling Technology)
      Market Size Base Year (Billions) ~USD 28.2 (2026)
      Revenue Forecast (Billions) ~USD 48.82 (2031)
      Segments Covered Profiling Technology, Type, Cancer Type, Products

      US Cancer Biomarkers Market Report Segmentation

      4 segment dimensions are covered across the global market.

      By Profiling Technology

      • Imaging Technologies
      • Omics Technologies

      By Type

      • 2D Gel Electrophoresis
      • Antibodies
      • Biopsy Instruments
      • Computed Tomography (Ct)
      • Genomics
      • Imaging Instruments
      • Immunoassay
      • In-Situ Hybridization (Ish)
      • Kits And Reagents
      • Magnetic Resonance Imaging (Mri)
      • Mammography
      • Mass Spectrometry
      • Next Generation Sequencing
      • Other Omics Technologies
      • Other Proteomics Technologies
      • Pathology-Based Instrument
      • Polymerase Chain Reaction
      • Positron Emission Tomography (Pet)
      • Probes
      • Protein Microarray
      • Proteomics
      • Ultrasound Imaging

      By Cancer Type

      • Bladder Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Kidney Cancer
      • Leukemia
      • Lung Cancer
      • Melanoma
      • Non-Hodgkin'S Lymphoma
      • Other Cancer Types
      • Prostate Cancer
      • Thyroid Cancer

      By Products

      • Bioinformatics Software
      • Consumables
      • Instruments

      US: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032

      Segment20242025202620272029203020312032CAGR (%)
      BIOPHARMACEUTICAL COMPANIES & CROS2198.724032661.72957.73690.94155.94706.75332.912.3
      DIAGNOSTIC LABORATORIES5083.25487.36002.66586.980138906.99957.111135.210.8
      OTHER END USERS372.8386.7406427.1475.7504.8537.9572.35.9
      RESEARCH AND ACADEMIC INSTITUTES1157.41258.71387.315341895.32123.52393.12698.111.7
      TOTAL8812.19535.710457.511505.61407515691.117594.819738.611.2

      Target Audience

      • Diagnostic Companies & IVD Manufacturers : Need US market sizing and growth forecasts to guide product development, clinical validation strategies, and commercial launch planning for cancer biomarker assays and companion diagnostics.
      • Pharmaceutical & Biotech Firms : Require detailed US market data to identify biomarker-driven drug development opportunities, companion diagnostic partnerships, and precision medicine market expansion strategies.
      • Healthcare Providers & Hospital Systems : Seek market intelligence on biomarker testing adoption, reimbursement trends, and clinical utility evidence to inform laboratory service expansion and precision oncology program investments.
      • Investment & Private Equity Firms : Need comprehensive US market analysis and growth projections to evaluate investment opportunities in cancer diagnostics companies and assess portfolio company valuations.
      • Healthcare Consultants & Policy Makers : Require US-specific market data and trend analysis to advise clients on precision medicine adoption, reimbursement policy development, and healthcare system modernization initiatives.

      Key Companies in the US Cancer Biomarkers Market

      CompanyHQOwnershipStrongest segments
      NANOSTRING TECHNOLOGIES, INCUnited States
      CELL SIGNALING TECHNOLOGY, INC.United States
      TRANSGENOMIC, INC.United States
      SANOFISpain
      SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging-based biomarker systems and software,In-vitro diagnostics instruments and consumables,Varian oncology platforms and services,
      BECTON, DICKINSON AND COMPANYUnited StatesPublic CompanyInstruments (flow cytometers, analyzers, automation),Consumables & reagents (antibodies, kits, collection products, media),
      MYRIAD GENETICSUnited StatesPublic CompanyHereditary cancer and germline oncology tests (e.g., MyRisk, BRACAnalysis CDx),Tumor-based prognostic and companion diagnostics (MyChoice CDx, Prolaris, EndoPredict, Precise Tumor),Other oncology-adjacent genomics and lab services within cancer workflows,
      SYSMEX CORPORATIONJapanPublic CompanyInstruments (hematology, coagulation, cell analysis platforms),Consumables (reagents, calibrators, controls, software-linked services),
      HOLOGIC, INC.United StatesPrivate CompanyBreast cancer imaging systems and software,Biopsy guidance systems and markers,Cytology and related consumables (ThinPrep),

      NANOSTRING TECHNOLOGIES, INC

      NanoString Technologies develops and commercializes molecular analysis platforms for gene expression profiling and genomic research.

      CELL SIGNALING TECHNOLOGY, INC.

      Cell Signaling Technology Inc. produces research antibodies, proteins, and assay kits for cell biology and life sciences research.

      TRANSGENOMIC, INC.

      Transgenomic Inc. provides genetic testing and molecular diagnostics solutions for disease detection and management.

      SANOFI

      Sanofi is a multinational pharmaceutical company developing and marketing medicines, vaccines, and diagnostic products.

      SIEMENS HEALTHINEERS AG

      Siemens Healthineers AG is a global medical technology company providing diagnostic imaging, laboratory diagnostics, and healthcare IT solutions.

      BECTON, DICKINSON AND COMPANY

      Becton, Dickinson and Company manufactures and distributes medical devices, laboratory equipment, and diagnostic systems.

      MYRIAD GENETICS

      Myriad Genetics is a molecular diagnostics company providing genetic testing and precision medicine solutions for cancer and other diseases.

      SYSMEX CORPORATION

      Sysmex Corporation manufactures and sells hematology, hemostasis, and clinical chemistry diagnostic systems and reagents.

      HOLOGIC, INC.

      Hologic Inc. develops and markets diagnostic and medical imaging systems, particularly for women's health and cancer detection.

      Reasons to Buy this Report

      • Market Size & Growth Validation : Obtain precise valuation data for the US market ($7.8B in 2026 to $15.2B in 2031) to benchmark competitive positioning and identify revenue opportunities in precision oncology.
      • Regional Opportunity Assessment : Understand US-specific market dynamics, healthcare infrastructure advantages, and reimbursement landscape to develop targeted go-to-market strategies for biomarker diagnostic products.
      • Investment Decision Support : Leverage detailed US market projections and growth drivers to support capital allocation decisions, M&A strategies, and partnership evaluations in the cancer diagnostics sector.
      • Competitive Intelligence : Analyze US market trends, adoption rates of precision medicine, and emerging biomarker applications to identify competitive gaps and differentiation opportunities.
      • Regulatory & Reimbursement Insights : Gain actionable intelligence on US FDA approval pathways, insurance coverage trends, and healthcare provider adoption patterns to accelerate product commercialization timelines.

      Frequently asked questions

      What is the current size of the US cancer biomarkers market in 2026?

      The US cancer biomarkers market is valued at $7,800 million in 2026, representing a significant segment of the global oncology diagnostics industry.

      What is the projected size of the US cancer biomarkers market by 2031?

      The US cancer biomarkers market is forecast to reach $15,157.3 million by 2031, nearly doubling from 2026 levels.

      What is the CAGR for the US cancer biomarkers market?

      The US cancer biomarkers market is expected to grow at a compound annual growth rate (CAGR) of 11.7% from 2026 to 2031.

      What are the primary drivers of growth in the US cancer biomarkers market?

      Key drivers include increasing adoption of precision oncology, rising demand for early cancer detection, expansion of companion diagnostics, liquid biopsy innovation, and growing reimbursement coverage in the US healthcare system.

      How does the US cancer biomarkers market compare to global trends?

      The US market grows at 11.7% CAGR, slightly outpacing the global rate of 11.6%, reflecting the US's advanced healthcare infrastructure, strong R&D investment, and robust regulatory environment.

      RESEARCH METHODOLOGY

      The objective of the study is to analyze key market dynamics, including drivers, opportunities, restraints, challenges, and key players' strategies. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players, the competitive landscape of the cancer biomarkers market will be analyzed, and market players will be evaluated on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.
      The four steps involved in estimating the market size are

      Secondary Research

      In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

      Primary Research

      In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess prospects.

      The following is a breakdown of the primary respondents

      Cancer Biomarkers Market Size, and Share

      Note 1: Others include sales, marketing, and product managers.
      Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.

      COMPANY NAME

      DESIGNATION

      Thermo Fisher (US)

      Sales Manager

      F. Hoffmann-La Roche AG (Switzerland)

      Product Manager

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total market size of cancer biomarkers. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • The key players in the industry have been identified through extensive secondary research
      • The revenues generated by leading players operating in the cancer biomarkers market have been determined through primary and secondary research
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

      Cancer Biomarkers Market : Top-Down and Bottom-Up Approach

      Cancer Biomarkers Market Top Down and Bottom Up Approach

      Data Triangulation

      After arriving at the overall market size using the process described above, the total market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      Cancer biomarkers are biological molecules produced by the body or a tumor in a person with cancer. Cancer biomarker testing helps differentiate alterations in the tumor. Biomarkers may be produced by the cancer tissue itself or by other cells in the body in response to cancer. It can also be found in the blood, stool, urine, tumor tissue, or other tissues or bodily fluids. Biomarkers can be DNA, RNA, proteins, or metabolomic profiles specific to the tumor. They enhance cancer detection and facilitate high-speed, noninvasive diagnosis using profiling technologies such as omics, imaging, immunoassays, and cytogenetics.

      Key Stakeholders

      • Product Manufacturers, Distributors, and Suppliers
      • Diagnostic Laboratories
      • Research Laboratories and CROs
      • Ambulatory Testing Centers
      • Contract Testing Laboratories
      • Academic Universities and Medical Research Centers
      • Research and Development (R&D) Centers

      Report Objectives

      • To define, segment, and forecast the cancer biomarkers market by profiling technology, cancer type, product, application, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market 
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to six regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries
      • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • To benchmark players within the market using the proprietary company evaluation matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
      • To study the impact of AI on the market, along with the macroeconomic outlook for each region

      Available customizations:

      MarketsandMarkets offers the following customizations for this market report.

      Product Analysis

      • Product matrix, which provides a detailed comparison of the product portfolio of each company in the cancer biomarkers market

      Country Information

      • Additional country-level analysis of the cancer biomarkers market

      Company Profiles

      • Additional five company profiles of players operating in the cancer biomarkers market.

      Get the Full Cancer Biomarkers Market Report

      Full forecast, segment splits, and company analysis for all Cancer Biomarkers Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status